Clinical Trials Browser

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT04575415 2020-10-20

BELLA

Unknown

272 enrolled

Thoracic

NSCLC

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

92 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Thoracic

Lung Neoplasms

NCT02514174 2020-03-30

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Phase 4 Completed

25 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02047903 2020-01-09

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Completed

161 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01953913 2019-08-12

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 3 Completed

542 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02595840 2019-04-19

Trans-MARBLE

Phase 2 Terminated

4 enrolled

Thoracic

Non-small-cell Lung Cancer With Somatic EGFR Mutations

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

30 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT01523587 2019-02-15

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Phase 3 Completed

795 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

EDDIS-a1

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

DELINOR

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Afatinib in NSCLC With HER2 Mutation

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

FHND9041

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Afatinib With CT and RT for EGFR-Mutant NSCLC

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

ERIS

Observational Study of Afatinib 30 mg Daily

NSCLC

CamBMT1

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

DARWIN1

AFACET

UpSwinG

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

TRUMP

ACE-Lung

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

LiquidLung-A

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Afatinib Osimertinib Sequencing NIS

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

BELLA

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Trans-MARBLE

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy